Previous 10 | Next 10 |
2023-05-04 16:25:12 ET Codexis press release ( NASDAQ: CDXS ): Q1 Non-GAAP EPS of -$0.39. Revenue of $12.98M (-63.3% Y/Y) misses by $1.11M . CDXS reiterated its 2023 total revenue guidance range of $63 million to $68 million, excluding enzyme sales related to Paxlo...
CDX-7108 Clinical Development Program Remains on Track Estimated Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Reiterates 2023 Total Revenue Guidance with Adjustments to Product vs. R&D Revenue Mix and Range on Gross Margin REDWOOD CITY, C...
2023-05-03 17:35:58 ET Codexis ( NASDAQ: CDXS ) is scheduled to announce Q1 earnings results on Thursday, May 4th, after market close. The consensus EPS Estimate is -$0.25 (-92.3% Y/Y) and the consensus Revenue Estimate is $14.09M (-60.1% Y/Y). Over the last 1 year, CD...
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be con...
REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annua...
2023-04-18 17:26:56 ET Gainers: PacWest Bancorp ( PACWP ) +9% . PacWest Bancorp ( PACW ) +8% . Intuitive Surgical ( ISRG ) +8% . Codexis ( CDXS ) +4% . Near Intelligence ( NIR ) +4% . Losers: CDW Corporation ( CDW ) ...
REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nomina...
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43 rd Annual Health Care Conference, being held March 6-...
Codexis, Inc. (CDXS) Q4 2022 Earnings Conference Call February 23, 2023, 16:30 ET Company Participants Stephen Dilly - President, CEO & Director Kevin Norrett - COO Sriram Ryali - CFO Conference Call Participants Steven Mah - Cowen Company Brandon C...
Codexis press release ( NASDAQ: CDXS ): Q4 GAAP EPS of $0.19 beats by $0.42 . Revenue of $30.4M (+24.1% Y/Y) beats by $1.48M . Total revenues are expected to be in the range of $63 million to $68 million, vs. consensus of $91.98M. For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...